

Anatara Lifesciences provides clinical trials update

MELBOURNE, 16 December 2021: Anatara Lifesciences (ASX: ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals, provides an update on progress of clinical trials in psychological functioning and irritable bowel syndrome, diarrhoea subtype (IBS-D).

On 16 November at the AGM, Anatara anticipated commencing recruitment for the psychological functioning trial by the end of November and interim results for the IBS-D trial in April 2022.

Commenting on progress made towards the human clinical studies, CEO Steve Lydeamore said, “We are about a month behind where we expected to be with both trials. While we always anticipated a pause in recruiting over the Christmas break, as well as the potential impact of diet and lifestyle during that period, investigational product was not received from India in time to commence recruitment for the psychological functioning trial prior to Christmas. We now anticipate commencing recruitment for that trial to be in mid-January 2022”.

“We are taking actions to recover trial participants in the IBS-D trial. Potential trial participants were excluded as their IBS Symptom Severity Scores (IBS-SSS) were marginally higher than the trial inclusion criteria. In the field of IBS clinical research severity is identified using the IBS-SSS questionnaire. For moderate sufferers the cut off score is below 300. In our screening we have identified a sizeable cohort with scores of 300-350 who have been excluded to date. Anatara applied for and received ethics approval to modify the criteria which has now expanded the pool of potential patients”.

Anatara is adding an additional site in Adelaide for the IBS-D trial which will target recruitment of up to 50 participants and has engaged Evrima, a specialist in patient identification and recruitment. Evrima will support Anatara’s IBS-D trial by both direct-to-patient and direct-to-clinician channels. Direct-to-patient will increase community awareness via social media, digital marketing campaigns and radio advertising. Direct-to-clinician will generate awareness within the GP community, as well as through the use of their proprietary software to identify potentially eligible patients via electronic health records in Australia.

3FDC trial in psychological functioning

3FDC is one of the components of Anatara’s GaRP (Gastrointestinal reprogramming) complementary medicine. GaRP is a combination of two different minitablets, which is under investigation in another study focused on diarrhoea predominant Irritable bowel syndrome (IBS-D). The different minitablets in the formulation target different parts of the gastrointestinal tract. 3FDC is targeted to release at the junction between the small and large intestine (ileocecal junction) and exert its effects on the microbiome in the large intestine. Since restoration of a healthy microbiome is considered important for gut-brain axis balance, the 3FDC components have been selected to explore their effect on depression, anxiety and stress symptoms in otherwise healthy individuals.

Anatara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

Suite 101, 55 Flemington Rd., North Melbourne, VIC 3051, Australia

Email info@anatara.com | Website anataralifesciences.com



This randomised, double-blinded, placebo-controlled study into the effects of 3FDC in adults with moderate anxiety, stress or depression will be conducted at CSIRO's Nutrition and Health Research Clinic in Adelaide. Approximately 100 participants will be randomised in a 1:1 manner to treatment with 3FDC or placebo which is dosed twice a day for 6 weeks.

CEO Steve Lydeamore commented, "There is a major unmet need and significant market opportunity for an evidence-based complementary medicine for stress, anxiety and depression. According to Beyond Blue a quarter of Australians will experience an anxiety condition in their lifetime. I am excited that Anatara's 3FDC dietary supplement may be of benefit to some of the many who experience these conditions. It is gratifying that Anatara's focus on gut health and integrity has allowed us to capitalise on our research in IBS with the potential to address other microbiome centric conditions. The current study has the potential, not only to help those suffering mood disorders, but to significantly add to our understanding of GaRP in non-IBS participants. "

GaRP trial in IBS-D (irritable bowel syndrome)

This study consists of two stages (Stage 1, Stage 2), with an interim analysis between stages. Stage 1 will assess the safety, tolerability and efficacy of two different strengths of GaRP against placebo in a 1:1:1 randomisation protocol. Following interim analysis, one dose will be selected, and the remaining participants recruited in a 1:1 randomisation protocol. Of the 200 planned participants, at least 90 will enrol in stage 1, and 110 participants will enrol in stage 2. For each participant in each stage, the study will last for 12 weeks; including 8 weeks of treatment, preceded by a 2-week screening/baseline period and followed by a 2-week washout period. Measurements will include a number of surveys including the IBS specific surveys: IBS-SSS (severity scoring system), IBS QoL (quality of life) and IBS-AR (adequate relief) and Bristol Stool Form Scale.

CEO Steve Lydeamore commented, "There is a major unmet need and significant market opportunity for an evidence-based complementary medicine for IBS. Anatara's GaRP has demonstrated that it has the potential to manage the devastating symptoms experienced by IBD and IBS patients, by addressing processes that contribute to the pathophysiology of these chronic bowel conditions."

Anatara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

Suite 101, 55 Flemington Rd., North Melbourne, VIC 3051, Australia

Email info@anatara.com | Website anataralifesciences.com



For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anataara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anataara.com	Eric Kuret Market Eye +61 (0) 417 311 335 eric.kuret@marketeye.com.au

About Anataara Lifesciences Ltd

Anataara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataara is a life sciences company with expertise in developing products for human and animal health. Anataara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anataara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anataara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

Suite 101, 55 Flemington Rd., North Melbourne, VIC 3051, Australia

Email info@anataara.com | Website anataralifesciences.com

